These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 27404557)
1. Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening. Pibiri I; Lentini L; Tutone M; Melfi R; Pace A; Di Leonardo A Eur J Med Chem; 2016 Oct; 122():429-435. PubMed ID: 27404557 [TBL] [Abstract][Full Text] [Related]
2. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives. Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488 [TBL] [Abstract][Full Text] [Related]
3. Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay. Lentini L; Melfi R; Di Leonardo A; Spinello A; Barone G; Pace A; Palumbo Piccionello A; Pibiri I Mol Pharm; 2014 Mar; 11(3):653-64. PubMed ID: 24483936 [TBL] [Abstract][Full Text] [Related]
4. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Sermet-Gaudelus I; Boeck KD; Casimir GJ; Vermeulen F; Leal T; Mogenet A; Roussel D; Fritsch J; Hanssens L; Hirawat S; Miller NL; Constantine S; Reha A; Ajayi T; Elfring GL; Miller LL Am J Respir Crit Care Med; 2010 Nov; 182(10):1262-72. PubMed ID: 20622033 [TBL] [Abstract][Full Text] [Related]
5. Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs. Pibiri I; Lentini L; Melfi R; Tutone M; Baldassano S; Ricco Galluzzo P; Di Leonardo A; Pace A Eur J Med Chem; 2018 Nov; 159():126-142. PubMed ID: 30278331 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Kerem E; Hirawat S; Armoni S; Yaakov Y; Shoseyov D; Cohen M; Nissim-Rafinia M; Blau H; Rivlin J; Aviram M; Elfring GL; Northcutt VJ; Miller LL; Kerem B; Wilschanski M Lancet; 2008 Aug; 372(9640):719-27. PubMed ID: 18722008 [TBL] [Abstract][Full Text] [Related]
7. Targeting Nonsense: Optimization of 1,2,4-Oxadiazole TRIDs to Rescue CFTR Expression and Functionality in Cystic Fibrosis Cell Model Systems. Pibiri I; Melfi R; Tutone M; Di Leonardo A; Pace A; Lentini L Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899265 [TBL] [Abstract][Full Text] [Related]
8. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Wilschanski M; Miller LL; Shoseyov D; Blau H; Rivlin J; Aviram M; Cohen M; Armoni S; Yaakov Y; Pugatsch T; Cohen-Cymberknoh M; Miller NL; Reha A; Northcutt VJ; Hirawat S; Donnelly K; Elfring GL; Ajayi T; Kerem E Eur Respir J; 2011 Jul; 38(1):59-69. PubMed ID: 21233271 [TBL] [Abstract][Full Text] [Related]
9. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Du M; Liu X; Welch EM; Hirawat S; Peltz SW; Bedwell DM Proc Natl Acad Sci U S A; 2008 Feb; 105(6):2064-9. PubMed ID: 18272502 [TBL] [Abstract][Full Text] [Related]
11. Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations. Mutyam V; Du M; Xue X; Keeling KM; White EL; Bostwick JR; Rasmussen L; Liu B; Mazur M; Hong JS; Falk Libby E; Liang F; Shang H; Mense M; Suto MJ; Bedwell DM; Rowe SM Am J Respir Crit Care Med; 2016 Nov; 194(9):1092-1103. PubMed ID: 27104944 [TBL] [Abstract][Full Text] [Related]
13. Ataluren/ivacaftor combination therapy: Two N-of-1 trials in cystic fibrosis patients with nonsense mutations. Peabody Lever JE; Mutyam V; Hathorne HY; Peng N; Sharma J; Edwards LJ; Rowe SM Pediatr Pulmonol; 2020 Jul; 55(7):1838-1842. PubMed ID: 32281737 [TBL] [Abstract][Full Text] [Related]
14. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. Linde L; Boelz S; Nissim-Rafinia M; Oren YS; Wilschanski M; Yaacov Y; Virgilis D; Neu-Yilik G; Kulozik AE; Kerem E; Kerem B J Clin Invest; 2007 Mar; 117(3):683-92. PubMed ID: 17290305 [TBL] [Abstract][Full Text] [Related]
15. Investigating REPAIRv2 as a Tool to Edit Melfi R; Cancemi P; Chiavetta R; Barra V; Lentini L; Di Leonardo A Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32640650 [TBL] [Abstract][Full Text] [Related]
16. Strategies against Nonsense: Oxadiazoles as Translational Readthrough-Inducing Drugs (TRIDs). Campofelice A; Lentini L; Di Leonardo A; Melfi R; Tutone M; Pace A; Pibiri I Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284579 [TBL] [Abstract][Full Text] [Related]
17. Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids. Zomer-van Ommen DD; Vijftigschild LA; Kruisselbrink E; Vonk AM; Dekkers JF; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM J Cyst Fibros; 2016 Mar; 15(2):158-62. PubMed ID: 26255232 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic Suppression of Nonsense Mutation: An Emerging Target in Multiple Diseases and Thrombotic Disorders. Asiful Islam M; Alam F; Kamal MA; Gan SH; Wong KK; Sasongko TH Curr Pharm Des; 2017; 23(11):1598-1609. PubMed ID: 27875971 [TBL] [Abstract][Full Text] [Related]
20. Synergy between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Mutations. McHugh DR; Cotton CU; Hodges CA Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]